European Pharmaceutical Review

MARCH 8, 2023

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. It was when my son developed depression and obsessive-compulsive disorder (OCD) that things changed for me, including my career focus. I believe we can and must do better.

Hospitals 52

Hospitals Drug Development 52

Quality Matters

NOVEMBER 11, 2022

FDA) workshop , my fellow panelist and I addressed the latest developments in the identification and control of nitrosamines in pharmaceutical products. Starting in 2018, concerning levels of these impurities were found in commonly prescribed medicines for blood pressure, diabetes, and other conditions. Earlier this year, at a U.S.

Packaging 52

Packaging Documentation Compounding Diabetes 52

PharmaShots

JUNE 8, 2023

It is more common in the population of southern Europe, North America, and Australia, and less common in northern Europe and Japan. Market Size:[5] The global systemic scleroderma treatment market size was $1,520M in 2021, 1588M in 2022 and it is expected to increase to $2467M by 2032, at a CAGR of 4.5%.

Immunity 40

Immunity Immunization 40

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Founded Year: 2007 No. of Shares: 1.5M Founded Year: 2007 No. of Shares: 1.5M The company bagged its $6.3M IPO in Jun’22 offering shares at $4.25/unit.

Vaccines 40

Vaccines Immunity Immunization Diabetes 40

pharmaphorum

MARCH 9, 2021

This thought leadership series has been paid for and developed with Kite, A Gilead Company. Lymphoma is the fifth most common cancer in the UK after breast, lung, prostate and bowel cancer. Lymphoma is the fifth most common cancer in the UK after breast, lung, prostate and bowel cancer.

Chemotherapy 52

Chemotherapy Communication Immunity Immunization 52

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. And all are predominantly prevented or treated with medicines that are decades old.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies Compounding Vaccines 95

pharmaphorum

JANUARY 9, 2023

This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. Stretched health systems have less time and money to adopt new products, except in exceptional circumstances, such as first ever treatments for serious conditions.

Vaccines 96

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 96

pharmaphorum

FEBRUARY 4, 2022

In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among payers in England, comparing assessments by NICE versus the NHS. Link between disease rarity and drug pricing.

Drug Pricing 96

Drug Pricing Drug Development 96

The Physician Pharmacist

OCTOBER 19, 2023

The Physician Pharmacist Do's and Don'ts 6 Most Common Questions About Transitioning From Pharmacy to Medicine The Art of Applying to Medical School (The Pharmacy Student Edition)! ️ Join us for an inspiring and informative Episode 6 of The Physician Pharmacist Podcast, where we have the privilege of sitting down with Dr. Brandon J.

Medical Schools 52

Medical Schools Hospitals Inpatient Pharmacy Technician 52

pharmaphorum

FEBRUARY 2, 2021

In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in reimbursement decisions among payers in Germany. The relationship between price and prevalence, among other factors. But this relationship was not straightforward in all cases.

Documentation 54

Documentation 54

Putting Patients First Blog

NOVEMBER 14, 2023

A study published in the Journal of Health Politics, Policy, and Law pointed out that allocation frameworks like SOFA could inadvertently discriminate against individuals with certain pre-existing conditions or disabilities.1 Finally, there must be transparency in how these allocation protocols are developed and implemented.

Communication 40

Communication Bioethics Hospitals Documentation 40

PharmaShots

MAY 11, 2023

Children have a 50% chance of developing the disease Age - ALS is common between the ages of 40 and the mid-60s Sex - Before, the age of 65, more men than women develop ALS. ALS is 20% more common in men than women. cases per 100,000 persons annually, whereas the prevalence is ~6 cases per 100,000.

Mayo Clinic 40

Mayo Clinic Compounding Communication 40

PharmaShots

MARCH 22, 2023

Sangamo granted Biogen the worldwide rights to develop and commercialize therapeutics for hemoglobinopathies including sickle cell disease and beta-thalassemia using Sangamo’s zinc-finger ZFN genome-editing technology. including a P-I milestone payment of $7.5M including a P-I milestone payment of $7.5M

Vaccines 40

Vaccines 40

The Thyroid Pharmacist

SEPTEMBER 9, 2022

Fatigue and low energy are common symptoms of hypothyroidism. Conventional endocrinologists often refer to the TSH test as the “gold standard” test for diagnosing and treating thyroid conditions. Sure, the thyroid medication helped; instead of sleeping for 12 hours, I only needed 11 hours of sleep. But I didn’t stop there.

Diabetes 98

Diabetes Dosage Compounding Immunity 98